natgillin/translations-raw huggingface dataset:
Therefore, at the time of the withdrawal, the CHMP's view was that a benefit of Kiacta had not been sufficiently demonstrated and any benefits did not outweigh the identified risks. 
Seepärast oli inimravimikomitee tagasivõtmise ajal seisukohal, et Kiacta kasulikkust ei olnud piisavalt tõendatud ning et see ei olnud suurem väljaselgitatud riskidest.
The effectiveness of Kiacta was studied in one main study involving 183 patients with AA amyloidosis, in which Kiacta was compared with placebo (a dummy treatment). 
Kiacta tõhusust uuriti ühes põhiuuringus, milles osales 183 patsienti, kellel oli AA-amüloidoos; uuringus võrreldi Kiactat patseeboga (näiv ravim).
The company informed the CHMP that the ongoing clinical trial with Kiacta is being stopped, so that it can carry out a second study to compare Kiacta with placebo. 
Ettevõte teatas inimravimikomiteele, et Kiacta kliinilised uuringud on peatatud, et ta saaks läbi viia teise uuringu, milles võrreldakse Kiactat platseeboga.
Kiacta is a medicine containing the active substance eprodisate disodium. 
Kiacta on ravim, mis sisaldab toimeainena naatriumeprodisaati.
Based on the review of the data and the company's response to the CHMP list of questions at the time of the withdrawal, the CHMP had given a negative opinion and did not recommend a marketing authorisation for Kiacta for the treatment of AA amyloidosis. 
Tuginedes esitatud andmete analüüsile ja ettevõtte vastustele inimravimikomitee esitatud küsimustele, oli komitee andnud taotluse tagasivõtmise ajal negatiivse arvamuse ega soovitanud anda Kiactale AAamüloidoosi ravis kasutamiseks müügiluba.
In addition, following an inspection of the site where the data from the study were analysed, the CHMP had concerns over the reliability of the study's findings because of the way the analysis was carried out. 
Pärast uuringu andmete analüüsikoha kontrollimist tekitas analüüsi viis inimravimikomiteel ka kahtlusi uuringu tulemuste usaldusväärsuse suhtes.
The most serious symptoms of the disease are caused by AA deposits building up in the kidneys and damaging them. 
Haiguse kõige raskemaid sümptomeid tekitavad neerudes moodustuvad ja neid kahjustavad A-amüloidi ladestused.
What were the main concerns of the CHMP? 
Mis oli inimravimikomitee ettevaatlikkuse peamiseks põhjuseks?
The active substance in Kiacta, eprodisate disodium, is expected to work by interfering with the formation of fibrils of AA, preventing the deposits from building up in the organs. 
Kiacta toimeaine naatriumeprodisaat eeldatavasti sekkub A-amüloidi fibriilide moodustumisse, takistades nende ladestumist elundites.
How is Kiacta expected to work? 
Mis on Kiacta eeldatav toime?
Although there was a suggestion that Kiacta may be active, the Committee concluded that another study would be needed to demonstrate the medicine's effectiveness. 
Kuigi Kiacta näis toimivat, arvas komitee, et ravimi tõhusust tuleks tõendada veel ühe uuringu alusel.
This is a rare, life-threatening disease that occurs in patients with long-lasting inflammation, most commonly due to rheumatoid arthritis. 
A-amüloidi tekitatav amüloidoos on haruldane eluohtlik haigus, mis esineb patsientidel, kellel on pikaajaline, enamasti reumatoidartriidist põhjustatud põletik.
The effects of Kiacta were first tested in experimental models before being studied in humans. 
Enne inimuuringuid kontrolliti Kiacta toimet muude katsetega.
The CHMP was concerned that the effectiveness of Kiacta in treating AA amyloidosis had not been demonstrated sufficiently in the single main study. 
Inimravimikomitee arvates ei tõendanud ainus põhiuuring Kiacta tõhusust AA-amüloidoosi raviks piisaval määral.
What was Kiacta expected to be used for? 
Milleks kavatseti Kiactat kasutada?
Amyloid A amyloidosis is caused by the build-up of insoluble ‘fibrils' (fine threads) of a protein called ‘amyloid A' (AA) in the organs of the body. 
AA-amüloidoosi põhjustab valk A-amüloidi (amyloid associated, AA) lahustamatute fibriilide (peente kiudude) moodustumine organismi elundites.
Kiacta was expected to be used to treat amyloid A amyloidosis. 
Kiacta oli ette nähtud A-amüloidi tekitatava amüloidoosi (AA-amüloidoos) raviks.
AA is produced in the body from a protein called ‘serum amyloid A', which is released by liver cells in response to inflammation. 
A-amüloidi toodab organismis seerumamüloid-A-eellasvalk, mida põletiku korral sünteesitakse maksas.
QUESTIONS AND ANSWERS ON THE WITHDRAWAL OF THE MARKETING APPLICATION for KIACTA 
TEAVE MÜÜGILOA TAOTLUSE TAGASIVÕTMISE KOHTA
Pilisborosjenő 2097 Hungary 
Pilisborosjenő 2097 Ungari
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCT, ROUTE OF ADMINISTRATION, APPLICANTS / MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 
I LISA RAVIMI NIMETUSTE, RAVIMVORMIDE JA TUGEVUSTE, MANUSTAMISTEEDE, MÜÜGILOA TAOTLEJATE/HOIDJATE LOETELU LIIKMESRIIKIDES
Treatment must not last longer than 12 weeks. 
Ravi ei tohi kesta kauem kui 12 nädalat.
They may also have episodes of depression. 
Patsientidel võib esineda ka depressiooniepisoode.
The full EPAR and risk management plan summary for Aripiprazole Accord can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Aripiprazole Accordi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
A risk management plan has been developed to ensure that Aripiprazole Accord is used as safely as possible. 
Töötati välja riskijuhtimiskava, et tagada Aripiprazole Accordi võimalikult ohutu kasutamine.
• schizophrenia, a mental illness with a number of symptoms, including disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (false beliefs). 
• skisofreenia - vaimuhaigus, millel on mitmesuguseid sümptomeid, sealhulgas mõtlemis- ja kõnehäired, hallutsinatsioonid (ebareaalsete asjade kuulmine või nägemine), kahtlustamine ja luulud.
Its exact mechanism of action is unknown, but it attaches to several different receptors on the surface of nerve cells in the brain. 
Selle täpne toimemehhanism ei ole teada, kuid aine seondub aju närvirakkude pinnal oleva mitme erineva retseptoriga.
What measures are being taken to ensure the safe and effective use of Aripiprazole Accord? 
Mis meetmed võetakse, et tagada Aripiprazole Accordi ohutu ja efektiivne kasutamine?
The Committee recommended that Aripiprazole Accord be approved for use in the EU. 
Komitee soovitas Aripiprazole Accordi kasutamise Euroopa Liidus heaks kiita.
The dose should be adjusted in patients who are taking other medicines that affect the way Aripiprazole Accord is broken down in the body. 
Annust tuleb kohandada patsientidel, kes võtavad teisi ravimeid, mis mõjutavad ravimi Aripiprazole Accord lagunemist organismis.
This means that aripiprazole acts like dopamine and 5hydroxytryptamine by activating these receptors, but less strongly than the neurotransmitters. 
See tähendab, et aripiprasool mõjub nagu dopamiin ja 5hüdroksütrüptamiin, aktiveerides neid retseptoreid, kuid vähem kui neurotransmitterid.
• bipolar I disorder, a mental illness in which patients have manic episodes (periods of abnormally high mood), alternating with periods of normal mood. 
• I tüüpi bipolaarne meeleoluhäire - vaimuhaigus, mille korral patsientide maaniaepisoodid (meeleolu äärmuslik tõus) vahelduvad normaalse meeleolu perioodidega.
Since dopamine and 5-hydroxytryptamine are involved in schizophrenia and bipolar disorder, aripiprazole helps to normalise the activity of the brain, reducing psychotic or manic symptoms and preventing them from returning. 
Et dopamiin ja 5-hüdroksütrüptamiin on seotud skisofreenia ja bipolaarse meeleoluhäirega, aitab aripiprasool ajutalitlust normaliseerida, leevendades psühhoosi- ja maaniasümptomeid ning ennetades nende taasteket.
To prevent manic episodes in adults, the same dose should be continued. 
Maaniaepisoodide ennetamiseks täiskasvanutel peab ravi jätkama sama annusega.
What is Aripiprazole Accord and what is it used for? 
Mis on Aripiprazole Accord ja milleks seda kasutatakse?
Aripiprazole Accord is available as tablets (5, 10, 15 and 30 mg) and can only be obtained with a prescription. 
Aripiprazole Accordi turustatakse tablettidena (5, 10, 15 ja 30 mg).
Aripiprazole Accord is used in patients aged 15 years or over; 
Ravimit Aripiprazole Accord kasutatakse patsientidel vanuses 15 aastat ja vanemad;
Other information about Aripiprazole Accord 
Muu teave Aripiprazole Accordi kohta
Because Aripiprazole Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Et Aripiprazole Accord on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
Aripiprazole Accord is used in adults to treat moderate to severe manic episodes and to prevent new manic episodes in adults who have responded to the medicine in the past. 
Ravimit Aripiprazole Accord kasutatakse mõõdukate ja raskete maaniaepisoodide raviks täiskasvanutel ja uute maaniaepisoodide ennetamiseks täiskasvanutel, kellel on varem tekkinud sellele ravimile ravivastus.
In addition, the company that markets Aripiprazole Accord will provide educational materials to be supplied to patients or their caregivers and to doctors to explain the safe use of the medicine in patients between 13 and 17 years. 
Ravimi Aripiprazole Accord tootja varustab ka patsiendid, nende hooldajad ja arstid teabepakmega, mis selgitab ravimi ohutut kasutamist 13-17-aastastel patsientidel.
Aripiprazole Accord is a medicine used in patients with the following mental illnesses: 
Ravimit Aripiprazole Accord kasutatakse järgmiste vaimuhaigustega patsientide raviks:
This means that Aripiprazole Accord is similar to a ‘reference medicine' already authorised in the European Union (EU) called Abilify. 
See tähendab, et Aripiprazole Accord on sarnane võrdlusravimiga Abilify, millel juba on Euroopa Liidus müügiluba.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Aripiprazole Accord has been shown to have comparable quality and to be bioequivalent to Abilify. 
Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Aripiprazole Accord võrreldav kvaliteet ja bioekvivalentsus ravimiga Abilify.
Aripiprazole Accord contains the active substance aripiprazole and is a ‘generic medicine'. 
Aripiprazole Accord sisaldab toimeainena aripiprasooli ja on geneeriline ravim.
For practical information about using Aripiprazole Accord, patients should read the package leaflet or contact their doctor or pharmacist. 
Kui vajate Aripiprazole Accordi kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Aripiprazole Accord, including the appropriate precautions to be followed by healthcare professionals and patients. 
Selle alusel lisati Aripiprazole Accordi omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
Aripiprazole is thought to act mainly by being a ‘partial agonist' for the receptors for the neurotransmitters dopamine and 5hydroxytryptamine (also called serotonin). 
Arvatakse, et aripiprasool mõjub põhiliselt neurotransmitterite dopamiini ja 5-hüdroksütrüptamiini (serotoniini) retseptorite osalise agonistina.
It is not intended to provide practical advice on how to use Aripiprazole Accord. 
Hindamisaruandes ei anta Aripiprazole Accordi kasutamise praktilisi nõuandeid.
This is a summary of the European public assessment report (EPAR) for Aripiprazole Accord. 
See on ravimi Aripiprazole Accord Euroopa avaliku hindamisaruande kokkuvõte.
Aripiprazole Accord is also used for up to 12 weeks to treat moderate to severe manic episodes in patients aged 13 years or over. 
Ravimit Aripiprazole Accord kasutatakse ka kuni 12 nädalat kestvaks mõõdukate kuni raskete maaniaepisoodide raviks patsientidel vanuses 13 aastat ja vanemad.
Because Aripiprazole Accord is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Abilify. 
Et Aripiprazole Accord on geneeriline ravim, piirdusid patsiendiuuringud katsetega, milles näidati Aripiprazole Accordi bioekvivalentsust võrdlusravimiga Abilify.
For more information about treatment with Aripiprazole Accord, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Kui vajate Aripiprazole Accordiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
For treating manic episodes in bipolar disorder, the recommended starting dose in adults is 15 mg once a day, either on its own or in combination with other medicines. 
Bipolaarse meeleoluhäirega kaasnevate maaniaepisoodide korral on täiskasvanute soovitatav algannus 15 mg üks kord ööpäevas ainsa ravimina või kombinatsioonis teiste ravimitega.
For further information, see the Summary of Product Characteristics (also part of the EPAR). 
Üksikasjalik teave on ravimi omaduste kokkuvõttes (mis on samuti Euroopa avaliku hindamisaruande osa).
Therefore, the CHMP's view was that, as for Abilify, the benefit outweighs the identified risk. 
Seetõttu on inimravimite komitee arvamusel, et nagu ka Abilify korral, ületab ravimi Aripiprazole Accord kasulikkus sellega kaasnevad riskid.
For schizophrenia, the recommended starting dose is 10 or 15 mg per day in adults, followed by a ‘maintenance' dose of 15 mg once a day. 
Soovitatav algannus täiskasvanutel skisofreenia ravis on 10 või 15 mg ööpäevas, millele järgneb säilitusannus 15 mg üks kord ööpäevas.
Aripiprazole Accord aripiprazole 
Aripiprazole Accord aripiprasool
This disrupts signals transmitted between brain cells by ‘neurotransmitters', chemicals that allow nerve cells to communicate with each other. 
See häirib ajurakkude vahel neurotransmitterite (virgatsainete) vahendatavaid närvisignaale.
In patients aged between 15 and 17 years, the starting dose is 2 mg a day (using an aripiprazole product available in liquid form), which is gradually increased to the recommended dose of 10 mg once a day. 
Algannus 15-17-aastastel patsientidel on 2 mg ööpäevas (kasutatakse vedelikuna turustatavat aripiprasooli ravimpreparaati), mida suurendatakse järk-järgult kuni soovitatava annuseni 10 mg üks kord ööpäevas.
The active substance in Aripiprazole Accord, aripiprazole, is an antipsychotic medicine. 
Ravimi Aripiprazole Accord toimeaine aripiprasool on antipsühhootikum.
Why is Aripiprazole Accord approved? 
Miks Aripiprazole Accord heaks kiideti?
For treating manic episodes in patients aged between 13 and 17 years, the starting dose is 2 mg a day (using an aripiprazole product available in liquid form), which is gradually increased to the recommended dose of 10 mg once a day. 
Maaniaepisoodide ravi algannus 13-17-aastastel patsientidel on 2 mg ööpäevas (kasutatakse vedelikuna turustatavat aripiprasooli ravimpreparaati), mida suurendatakse järk-järgult kuni soovitatava annuseni 10 mg üks kord ööpäevas.
How does Aripiprazole Accord work? 
Kuidas Aripiprazole Accord toimib?
How is Aripiprazole Accord used? 
Kuidas Aripiprazole Accordi kasutatakse?
What are the benefits and risks of Aripiprazole Accord? 
Milles seisneb Aripiprazole Accordi kasulikkus ja mis riskid ravimiga kaasnevad?
How has Aripiprazole Accord been studied? 
Kuidas Aripiprazole Accordi uuriti?
What measures are being taken to ensure the safe and effective use of Remicade? 
Mis meetmed võetakse, et tagada Remicade ohutu ja efektiivne kasutamine?
Other information about Remicade 
Muu teave Remicade kohta
Further information on Remicade can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Remicade. 
Lisateave Remicade kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/Remicade.
Remicade received a marketing authorisation valid throughout the EU on 13 August 1999. 
Remicade müügiluba, mis kehtib kogu Euroopa Liidus, anti 13. augustil 1999.
The European Medicines Agency decided that Remicade's benefits are greater than its risks and it can be authorised for use in the EU. 
Euroopa Ravimiamet otsustas, et Remicade kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
It is usually used when other medicines or treatments have failed, in adults with the following diseases: 
Seda kasutatakse tavaliselt juhul, kui muud ravimid või raviviisid on osutunud ebaefektiivseks, täiskasvanutel järgmiste haiguste raviks:
As for all medicines, data on the use of Remicade are continuously monitored. 
Nagu kõigi ravimite puhul, teostatakse Remicade kasutamise kohta pidevat järelevalvet.
What is Remicade and what is it used for? 
Mis on Remicade ja milleks seda kasutatakse?
Remicade is given as an infusion lasting one or two hours. 
Remicadet manustatakse 1 või 2 tundi kestva infusioonina.
To reduce the risk of infusion-related reactions, patients may be given other medicines before or during treatment with Remicade or the infusion time may be slowed down. 
Infusioonireaktsioonide riski vähendamiseks võidakse patsientidele anda enne ravi Remicadega või ravi ajal muid ravimeid, samuti võidakse infusiooni aeglustada.
A sixth study in 508 adult patients looked at the number of patients whose symptoms improved and who did not need additional treatment with corticosteroids (other medicines used in Crohn's disease). 
Kuuendas, 508 täiskasvanud patsiendi uuringus vaadeldi nende patsientide arvu, kelle sümptomid vähenesid ja kes ei vajanud lisaravi kortikosteroididega (samuti Crohni tõve ravimid).
Remicade is usually given as 3 mg per kilogram body weight in rheumatoid arthritis, although the dose can be increased if necessary. 
Reumatoidartriidi raviks manustatakse Remicadet tavaliselt 3 mg kehamassi kg kohta, kuid vajaduse korral tohib annust suurendada.
The effects of adding Remicade to existing treatment have also been studied in 103 children and adolescents with Crohn's disease who were aged between 6 and 17 years. 
Remicade lisamist olemasolevale ravile uuriti ka 103 Crohni tõvega 6-17-aastasel lapsel ja noorukil.
Most of the patients showed a reduction in symptoms after adding Remicade to their existing treatment. 
Enamikul patsientidel vähenesid haiguse sümptomid, kui nende olemasolevale ravile lisati Remicadet.
For more information about using Remicade, see the package leaflet or contact your doctor or pharmacist. 
Lisateavet Remicade kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
The most common side effects with Remicade (seen in more than 1 patient in 10) are viral infections (such as flu or cold sores), headache, upper respiratory tract infection (colds), sinusitis (inflammation of the sinuses), nausea (feeling sick), abdominal pain (stomach ache), infusion-related reactions and pain. 
Remicade kõige sagedamad kõrvalnähud (esinesid enam kui 1 patsiendil 10st) on viirusinfektsioonid (nt gripp või vöötohatis), peavalu, ülemiste hingamisteede infektsioonid (külmetus), sinusiit (põskkoopapõletik), iiveldus, kõhuvalu, infusioonireaktsioonid ja valu.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Remicade have also been included in the summary of product characteristics and the package leaflet. 
Remicade ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
Side effects reported with Remicade are carefully evaluated and any necessary action taken to protect patients. 
Remicade kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
What are the risks associated with Remicade? 
Mis riskid Remicadega kaasnevad?
In a study with 60 children aged between 6 and 17 years with ulcerative colitis 73% of patients responded to treatment with Remicade at week eight (44 out of 60). 
60 haavandilise koliidiga 6-17-aastase lapse uuringus tekkis ravivastus 8. nädalal 73%-l patsientidest (44 lapsel 60st).
By blocking TNF-alpha, infliximab improves the inflammation and other symptoms of the diseases. 
TNF-α blokeerimisega leevendab infliksimaab põletikku ja muid nende haiguste sümptomeid.
The patients were treated for 6 months with Remicade, another medicine azathioprine, or the combination of Remicade and azathioprine. 
Patsiente raviti 6 kuud Remicade, teise ravimi asatiopriini või Remicade ja asatiopriini kombinatsiooniga.
Remicade alone and in combination with azathioprine was more effective than azathioprine alone. 
Remicade ainsa ravimina või koos asatiopriiniga oli efektiivsem kui ainult asatiopriin.
Remicade is also used in patients aged between 6 and 17 years with severe, active Crohn's disease or severely active ulcerative colitis, when they have not responded to or cannot take other medicines or treatments. 
Remicadet kasutatakse ka 6-17-aastastel patsientidel, kellel on raske aktiivne Crohni tõbi või raske aktiivne haavandiline koliit, kui neil pole tekkinud teiste ravimitega ravivastust või nad ei saa teisi ravimeid või raviviise kasutada.
Ulcerative colitis, ankylosing spondylitis and psoriatic arthritis For ulcerative colitis (728 adults), ankylosing spondylitis (70 adults) and psoriatic arthritis (104 adults), Remicade has been compared with placebo. 
Haavandiline koliit, anküloseeriv spondüliit ja psoriaatiline artriit Remicadet võrreldi platseeboga haavandilise koliidi (728 täiskasvanut), anküloseeriva spondüliidi (70 täiskasvanut) ja psoriaatilise artriidiga (104 täiskasvanut) patsientidel.
How is Remicade used? 
Kuidas Remicadet kasutatakse?
Remicade must not be used in patients who have experienced hypersensitivity (allergy) to infliximab in the past, or who are hypersensitive (allergic) to mouse proteins or any of the other ingredients of Remicade. 
Remicadet ei tohi kasutada patsiendid, kellel on esinenud infliksimaabi suhtes ülitundlikkus (allergia) või kes on hiirevalkude või Remicade mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
Remicade has been studied in a total of 1,432 patients with rheumatoid arthritis in two studies. 
Remicadet uuriti kahes uuringus kokku 1432 reumatoidartriidiga patsiendil.
For the full list of side effects of Remicade, see the package leaflet. 
Remicade kõrvalnähtude täielik loetelu on pakendi infolehel.
Remicade is an anti-inflammatory medicine. 
Remicade on põletikuvastane ravim.
In these studies Remicade produced a greater improvement in symptoms, led to fistulae healing in more patients and increased the time that patients continued to respond to treatment. 
Nendes uuringutes vähenesid sümptomid Remicade kasutamisel rohkem, samuti paranesid fistulid suuremal arvul patsientidest ning ravivastus püsis kauem.
What benefits of Remicade have been shown in studies? 
Milles seisneb uuringute põhjal Remicade kasulikkus?
The active substance in Remicade, infliximab, is a monoclonal antibody, a type of protein that has been designed to recognise and attach to a specific structure (called an antigen) in the body. 
Remicade toimeaine infliksimaab on monoklonaalne antikeha (teatud valk), mis tunneb ära organismis leiduva teatud aine (antigeeni) ja seondub sellega.
This messenger is involved in causing inflammation and is found at high levels in patients with the diseases that Remicade is used to treat. 
See virgatsaine osaleb põletiku tekitamisel ning selle sisaldus on suur nende haigustega patsientidel, mida ravitakse Remicadega.
In a study in 627 adults with psoriasis, Remicade led to a greater improvement in symptoms than placebo. 
Uuringus, milles osales 627 psoriaasiga täiskasvanut, vähenesid Remicade rühmas sümptomid rohkem kui platseeborühmas.